Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome.

[1]  J. Norton,et al.  Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. , 1990, Gastroenterology.

[2]  R. Jensen,et al.  Zollinger-Ellison syndrome. Recent advances in the management of the gastrinoma. , 1990, Gastroenterology clinics of North America.

[3]  D. Andersen.  Current diagnosis and management of Zollinger-Ellison syndrome. , 1989, Annals of surgery.

[4]  R. Jensen,et al.  Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. , 1989, Gastroenterology clinics of North America.

[5]  R. Jensen,et al.  Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. , 1989, Gastroenterology.

[6]  J. Norton,et al.  Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome. , 1989, Gastroenterology.

[7]  J. Norton,et al.  A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. , 1988, Surgery.

[8]  K. A. Lloyd-Davies,et al.  Omeprazole in the treatment of Zollinger—Ellison syndrome: a 4‐year international study , 1988, Alimentary pharmacology & therapeutics.

[9]  C. Fenger,et al.  Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial , 1988, British medical journal.

[10]  P. Lundborg,et al.  Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. , 1988, Gut.

[11]  R. Jensen,et al.  Zollinger-Ellison syndrome. Current concepts in diagnosis and management. , 1987, The New England journal of medicine.

[12]  R. Jensen,et al.  Cimetidine pharmacokinetics in patients with Zollinger-Ellison syndrome. , 1987, Gastroenterology.

[13]  J. Norton,et al.  Role of selective angiography in the management of patients with Zollinger-Ellison syndrome. , 1987, Gastroenterology.

[14]  J. Norton,et al.  Prospective study of the ability of computed axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. , 1987, Gastroenterology.

[15]  J. Jansen,et al.  DOUBLE-BLIND MULTICENTRE COMPARISON OF OMEPRAZOLE AND RANITIDINE IN THE TREATMENT OF REFLUX OESOPHAGITIS , 1987, The Lancet.

[16]  G. Sachs,et al.  Inhibition of (H+ + K+)-ATPase by omeprazole in isolated gastric vesicles requires proton transport. , 1987, Biochimica et biophysica acta.

[17]  R. Jensen,et al.  Famotidine in the therapy of gastric hypersecretory states. , 1986, The American journal of medicine.

[18]  G. Porro,et al.  A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. , 1986, Journal of clinical gastroenterology.

[19]  P. Lindberg,et al.  The mechanism of action of the gastric acid secretion inhibitor omeprazole. , 1986, Journal of medicinal chemistry.

[20]  S. Clissold,et al.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. , 1986, Drugs.

[21]  S. Rune,et al.  Development of cimetidine resistance in the Zollinger-Ellison syndrome. , 1985, Gut.

[22]  C. Hawkey,et al.  Intravenous omeprazole rapidly raises intragastric pH. , 1985, Gut.

[23]  J. Rask-Madsen,et al.  Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. , 1985, The New England journal of medicine.

[24]  R. Jensen,et al.  Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. , 1985, Gastroenterology.

[25]  R. Jensen,et al.  Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. , 1985, Gastroenterology.

[26]  R. Jensen,et al.  Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states. , 1984, The American journal of medicine.

[27]  E. C. Wood,et al.  Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. , 1984, Gut.

[28]  J. Jansen,et al.  Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. , 1984, The New England journal of medicine.

[29]  E. Fellenius,et al.  Differentiation among inhibitory actions of omeprazole, cimetidine, and SCN- on gastric acid secretion. , 1983, The American journal of physiology.

[30]  U. Haglund,et al.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. , 1983, Gut.

[31]  A. Somogyi,et al.  Cimetidine plasma concentration‐response relationships , 1981, Clinical pharmacology and therapeutics.

[32]  G. Sachs,et al.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase , 1981, Nature.

[33]  J. Gardner,et al.  H2-Histamine receptor blocking agents in the Zollinger-Ellison syndrome. Experience in seven cases and implications for long-term therapy. , 1977, Annals of internal medicine.

[34]  H C Lee,et al.  Gastric adenosine triphosphatases: a review of their possible role in HCl secretion. , 1977, Gastroenterology.

[35]  P. Narang,et al.  Improved procedure for quantitation of omeprazole and metabolites using reversed-phase high-performance liquid chromatography. , 1988, Journal of chromatography.

[36]  T. Lind,et al.  Effect of omeprazole on gastric acid secretion in man. , 1986, Scandinavian journal of gastroenterology. Supplement.

[37]  V. Go.  The Exocrine pancreas : biology, pathobiology, and diseases , 1986 .

[38]  T. Lind,et al.  Intravenous omeprazole: effect on 24-hour intragastric pH in duodenal ulcer patients. , 1986, Digestion.

[39]  C. Regårdh.  Pharmacokinetics and metabolism of omeprazole in man. , 1986, Scandinavian journal of gastroenterology. Supplement.

[40]  D. Jones,et al.  Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. , 1985, Gastroenterology.

[41]  C. Regårdh,et al.  Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. , 1985, Scandinavian journal of gastroenterology. Supplement.

[42]  H. Ostensen,et al.  The incidence of peptic ulcer disease related to occupation in the northern part of Norway. A prospective epidemiological and radiological study. , 1985, Scandinavian journal of gastroenterology.

[43]  R. Jensen,et al.  Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion. , 1984, Annals of internal medicine.

[44]  M. Gibaldi.  Biopharmaceutics and clinical pharmacokinetics , 1977 .